Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 4, 2024
Daily News
April 4, 2024
- Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
- Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
- Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
- FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
- Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
- Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
- Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
- PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…